Literature DB >> 6940137

Immunodiagnosis of hepatitis B with high-affinity IgM monoclonal antibodies.

J R Wands, R I Carlson, H Schoemaker, K J Isselbacher, V R Zurawski.   

Abstract

High-affinity monoclonal IgG and IgM antibodies to hepatitis B surface antigen (HBsAg) have been prepared and their functional capabilities explored by means of solid-phase radioimmunoassays. 125I-labeled HBsAg binding studies indicated that monoclonal IgM antibodies against HBsAg (anti-HBs) coupled to a solid-phase support quantitatively bound more HbsAg at a faster rate than conventionally prepared anti-HBs reagents or other high-affinity IgG monoclonal anti-HBs antibodies. Consequently, IgM anti-HBs was also radiolabeled, and an IgM-IgM radioimmunoassay was developed for the immunodiagnosis of hepatitis B. The lower limit of this assay was approximately 100 pg +/- 30 (SEM) of HBsAg per ml of serum. Compared to available commercial radioassays, preliminary studies have shown the IgM-IgM assay to have increased sensitivity, which improved the detection of a HBsAg-associated determinant in acute hepatitis and post transfusion hepatitis. It is probable that the multivalent interaction between monoclonal IgM anti-HBs and the polydeterminant HBsAg is important in augmenting the performance of this monoclonal assay.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6940137      PMCID: PMC319978          DOI: 10.1073/pnas.78.2.1214

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  20 in total

1.  Continuous cultures of fused cells secreting antibody of predefined specificity.

Authors:  G Köhler; C Milstein
Journal:  Nature       Date:  1975-08-07       Impact factor: 49.962

2.  POLYMORPHISMS OF THE SERUM PROTEINS AND THE DEVELOPMENT OF ISO-PRECIPITINS IN TRANSFUSED PATIENTS.

Authors:  B S BLUMBERG
Journal:  Bull N Y Acad Med       Date:  1964-05

3.  Antibody affinity and valence in viral neutralization.

Authors:  S E Blank; G A Leslie; L W Clem
Journal:  J Immunol       Date:  1972-03       Impact factor: 5.422

4.  The influence of polyvalency on the binding properties of antibodies.

Authors:  D M Crothers; H Metzger
Journal:  Immunochemistry       Date:  1972-03

5.  Virus-like particles in serum of patients with Australia-antigen-associated hepatitis.

Authors:  D S Dane; C H Cameron; M Briggs
Journal:  Lancet       Date:  1970-04-04       Impact factor: 79.321

Review 6.  Structure and function of gamma M macroglobulins.

Authors:  H Metzger
Journal:  Adv Immunol       Date:  1970       Impact factor: 3.543

7.  An antigen detected in the blood during the incubation period of serum hepatitis.

Authors:  A M Prince
Journal:  Proc Natl Acad Sci U S A       Date:  1968-07       Impact factor: 11.205

8.  Biophysical and biochemical heterogeneity of purified hepatitis B antigen.

Authors:  G R Dreesman; F B Hollinger; J R Suriano; R S Fujioka; J P Brunschwig; J L Melnick
Journal:  J Virol       Date:  1972-09       Impact factor: 5.103

9.  The labelling of proteins to high specific radioactivities by conjugation to a 125I-containing acylating agent.

Authors:  A E Bolton; W M Hunter
Journal:  Biochem J       Date:  1973-07       Impact factor: 3.857

10.  Serial studies of hepatitis-associated antigen and antibody in patients receiving antitumor chemotherapy for myeloproliferative and lymphoproliferative disorders.

Authors:  J R Wands; C M Chura; F J Roll; W C Maddrey
Journal:  Gastroenterology       Date:  1975-01       Impact factor: 22.682

View more
  19 in total

1.  Structural analysis of hepatitis B surface antigen by monoclonal antibodies.

Authors:  E Ben-Porath; J R Wands; R A Marciniak; M A Wong; L Hornstein; R Ryder; M Canlas; A Lingao; K J Isselbacher
Journal:  J Clin Invest       Date:  1985-10       Impact factor: 14.808

2.  Detection of hepatitis A virus and antibody by solid-phase radioimmunoassay and enzyme-linked immunosorbent assay with monoclonal antibodies.

Authors:  A G Coulepis; M F Veale; A MacGregor; M Kornitschuk; I D Gust
Journal:  J Clin Microbiol       Date:  1985-07       Impact factor: 5.948

3.  Comparison of a monoclonal antibody with a polyclonal serum in an enzyme-linked immunosorbent assay for detecting adenovirus.

Authors:  L J Anderson; E Godfrey; K McIntosh; J C Hierholzer
Journal:  J Clin Microbiol       Date:  1983-09       Impact factor: 5.948

4.  Antigenic analysis of woodchuck hepatitis virus surface antigen with site-specific radioimmunoassays.

Authors:  P J Cote; R E Engle; C A Langer; A Ponzetto; J L Gerin
Journal:  J Virol       Date:  1984-03       Impact factor: 5.103

5.  Specificity of antibodies elicited by a synthetic peptide having a sequence in common with a fragment of a virus protein, the hepatitis B surface antigen.

Authors:  A R Neurath; S B Kent; N Strick
Journal:  Proc Natl Acad Sci U S A       Date:  1982-12       Impact factor: 11.205

6.  Hepatitis B virus infection and primary liver cancer--an unfolding story.

Authors:  D A Shafritz
Journal:  West J Med       Date:  1984-05

7.  Selecting binding and complement-mediated lysis of human hepatoma cells (PLC/PRF/5) in culture by monoclonal antibodies to hepatitis B surface antigen.

Authors:  D Shouval; J R Wands; V R Zurawski; K J Isselbacher; D A Shafritz
Journal:  Proc Natl Acad Sci U S A       Date:  1982-01       Impact factor: 11.205

8.  Establishment and characterization of a new human hepatocellular carcinoma cell line.

Authors:  L He; K J Isselbacher; J R Wands; H M Goodman; C Shih; A Quaroni
Journal:  In Vitro       Date:  1984-06

9.  Human anti-idiotype antibodies in cancer patients: Is the modulation of the immune response beneficial for the patient?

Authors:  H Koprowski; D Herlyn; M Lubeck; E DeFreitas; H F Sears
Journal:  Proc Natl Acad Sci U S A       Date:  1984-01       Impact factor: 11.205

10.  Hepatitis B viral antigenic structure: signature analysis by monoclonal radioimmunoassays.

Authors:  J R Wands; M A Wong; J Shorey; R D Brown; R A Marciniak; K J Isselbacher
Journal:  Proc Natl Acad Sci U S A       Date:  1984-04       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.